Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study

被引：15

作者：

Persano, Mara ^{[1
]}

Rimini, Margherita ^{[2
]}

Tada, Toshifumi ^{[3
]}

Suda, Goki ^{[4
]}

Shimose, Shigeo ^{[5
]}

Kudo, Masatoshi ^{[6
]}

Cheon, Jaekyung ^{[7
]}

Finkelmeier, Fabian ^{[8
]}

Lim, Ho Yeong ^{[9
]}

Rimassa, Lorenza ^{[10
,11
]}

Presa, Jose ^{[12
]}

Masi, Gianluca ^{[13
,14
]}

Yoo, Changhoon ^{[15
]}

Lonardi, Sara ^{[16
]}

Tovoli, Francesco ^{[17
]}

Kumada, Takashi ^{[18
]}

Sakamoto, Naoya ^{[4
]}

Iwamoto, Hideki ^{[5
]}

Aoki, Tomoko ^{[6
]}

Chon, Hong Jae ^{[7
]}

Himmelsbach, Vera ^{[8
]}

Pressiani, Tiziana ^{[11
]}

Kawaguchi, Takumi ^{[5
]}

Montes, Margarida ^{[12
]}

Vivaldi, Caterina ^{[13
,14
]}

Solda, Caterina ^{[16
]}

Piscaglia, Fabio ^{[17
]}

Hiraoka, Atsushi ^{[19
]}

Sho, Takuya ^{[4
]}

Niizeki, Takashi ^{[5
]}

Nishida, Naoshi ^{[5
]}

Steup, Christoph ^{[8
]}

Iavarone, Massimo ^{[20
]}

Di Costanzo, Giovanni ^{[21
]}

Marra, Fabio ^{[22
]}

Scartozzi, Mario ^{[1
]}

Tamburini, Emiliano ^{[23
]}

Cabibbo, Giuseppe ^{[24
]}

Foschi, Francesco Giuseppe ^{[25
]}

Silletta, Marianna ^{[26
]}

Hirooka, Masashi ^{[27
]}

Kariyama, Kazuya ^{[28
]}

Tani, Joji ^{[29
]}

Atsukawa, Masanori ^{[30
]}

Takaguchi, Koichi ^{[31
]}

Itobayashi, Ei ^{[32
]}

Fukunishi, Shinya ^{[33
]}

Tsuji, Kunihiko ^{[34
]}

Ishikawa, Toru ^{[35
]}

Tajiri, Kazuto ^{[36
]}

机构：

[1] Univ Hosp Cagliari, Med Oncol, Cagliari, Italy

[2] IRCCS San Raffaele Hosp, Dept Med Oncol, Via Olgettina 60, Milan, Italy

[3] Japanese Red Cross Himeji Hosp, Dept Internal Med, Himeji, Hyogo, Japan

[4] Hokkaido Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Kita Ku, North 15,West 7, Sapporo, Hokkaido 0608638, Japan

[5] Kurume Univ, Dept Med, Div Gastroenterol, Sch Med, Kurume, Fukuoka 8300011, Japan

[6] Kindai Univ, Dept Gastroenterol & Hepatol, Fac Med, Higashiosaka, Osaka, Japan

[7] CHA Univ Sch Med, CHA Bundang Med Ctr, Dept Med Oncol, Seongnam, South Korea

[8] Goethe Univ, Univ Hosp Frankfurt, Dept Internal Med 1, Frankfurt, Germany

[9] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Dept Med, Seoul, South Korea

[10] Humanitas Univ, Dept Biomed Sci, Milan, Italy

[11] IRCCS Humanitas Res Hosp, Humanitas Canc Ctr, Milan, Italy

[12] Liver Unit CHTMAD, Vila Real, Portugal

[13] Univ Hosp Pisa, Unit Med Oncol 2, Pisa, Italy

[14] Univ Pisa, Dept Translat Res & New Technol Med & Surg, Pisa, Italy

[15] Univ Ulsan, ASAN Med Ctr, Dept Oncol, Coll Med, 88 Olymp Ro 43 Gil, Seoul 05505, South Korea

[16] Veneto Inst Oncol IOV IRCCS, Oncol Unit 1, Padua, Italy

[17] IRCCS Azienda Osped Univ Bologna, Div Internal Med Hepatobiliary & Immunoallerg Dis, Via Albertoni 15, Bologna, Italy

[18] Gifu Kyoritsu Univ, Dept Nursing, Ogaki, Japan

[19] Ehime Prefectural Cent Hosp, Gastroenterol Ctr, Matsuyama, Ehime, Japan

[20] Fdn IRCCS Ca Granda Osped Maggiore Policlin Milan, Div Gastroenterol & Hepatol, Milan, Italy

[21] Dept Hepatol, I-80131 Naples, Italy

[22] Univ Firenze, Dipartimento Med Sperimentale & Clin, Florence, Italy

[23] Tricase City Hosp, Dept Oncol & Palliat Care, Cardinale G Panico, Tricase, Italy

[24] Univ Palermo, Dept Hlth Promot Mother & Child Care Internal Med, Sect Gastroenterol & Hepatol, PROMISE, I-90127 Palermo, Italy

[25] Osped Infermi Faenza, Dept Internal Med, Faenza, Italy

[26] Policlin Univ Campus Biomed, Div Med Oncol, Rome, Italy

[27] Ehime Univ, Dept Gastroenterol & Metabol, Grad Sch Med, Matsuyama, Ehime, Japan

[28] Okayama City Hosp, Dept Gastroenterol, Okayama, Japan

[29] Kagawa Univ, Dept Gastroenterol & Hepatol, Takamatsu, Kagawa, Japan

[30] Nippon Med Sch, Dept Internal Med, Div Gastroenterol & Hepatol, Tokyo, Japan

[31] Kagawa Prefectural Cent Hosp, Dept Hepatol, Takamatsu, Kagawa, Japan

[32] Asahi Gen Hosp, Dept Gastroenterol, Asahi, Japan

[33] Osaka Med & Pharmaceut Univ, Dept Gastroenterol, Osaka, Japan

[34] Teine Keijinkai Hosp, Ctr Gastroenterol, Sapporo, Hokkaido, Japan

[35] Saiseikai Niigata Hosp, Dept Gastroenterol, Niigata, Japan

[36] Toyama Univ Hosp, Dept Gastroenterol, Toyama, Japan

[37] Japanese Red Cross Matsuyama Hosp, Hepatobiliary Ctr, Matsuyama, Ehime, Japan

[38] Ogaki Municipal Hosp, Dept Gastroenterol & Hepatol, Ogaki, Japan

[39] Japanese Red Cross Takamatsu Hosp, Dept Gastroenterol, Takamatsu, Kagawa, Japan

[40] Hyogo Med Univ, Dept Internal Med, Div Gastroenterol & Hepatol, Nishinomiya, Hyogo, Japan

[41] Gunma Saiseikai Maebashi Hosp, Dept Gastroenterol, Maebashi, Gumma, Japan

[42] Natl Hosp Org Takasaki Gen Med Ctr, Dept Clin Res, Takasaki, Gumma, Japan

[43] Otakanomori Hosp, Div Gastroenterol & Hepatol, Kashiwa, Chiba, Japan

[44] Hamamatsu Univ Sch Med, Dept Hepatol, Hamamatsu, Shizuoka, Japan

[45] Kansai Med Univ, Dept Surg, Osaka, Japan

[46] Natl Hosp Org Takasaki Gen Med Ctr, Dept Gastroenterol, Takasaki, Gumma, Japan

[47] Sarah Cannon Res Inst UK, Drug Dev Unit, London, England

[48] Univ Vita Salute San Raffaele, IRCCS San Raffaele Sci Inst Hosp, Dept Oncol, Milan, Italy

来源：

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY | 2023年 / 149卷 / 09期

关键词：

Advanced HCC; Atezolizumab plus bevacizumab; First-line therapy; Lenvatinib; 1ST-LINE TREATMENT; ADVERSE EVENTS; SORAFENIB; IMMUNOTHERAPY; SURVIVAL; PATTERNS; CRITERIA;

D O I：

10.1007/s00432-022-04512-1

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose The purpose of this study is to compare response rates of lenvatinib and atezolizumab plus bevacizumab, in first-line real-world setting. Methods Overall cohort included Western and Eastern hepatocellular carcinoma (HCC) patient populations from 46 centres in 4 countries (Italy, Germany, Japan, and Republic of Korea). Results 1312 patients were treated with lenvatinib, and 823 patients were treated with atezolizumab plus bevacizumab. Objective response rate (ORR) was 38.6% for patients receiving lenvatinib, and 27.3% for patients receiving atezolizumab plus bevacizumab (p < 0.01; odds ratio 0.60). For patients who achieved complete response (CR), overall survival (OS) was not reached in both arms, but the result from univariate Cox regression model showed 62% reduction of death risk for patients treated with atezolizumab plus bevacizumab (p = 0.05). In all multivariate analyses, treatment arm was not found to be an independent factor conditioning OS. Comparing ORR achieved in the two arms, there was a statistically significant difference in favor of lenvatinib compared to atezolizumab plus bevacizumab in all subgroups except for Eastern patients, Child-Pugh B patients, presence of portal vein thrombosis, alpha-feto-protein >= 400 ng/mL, presence of extrahepatic disease, albumin-bilirubin (ALBI) grade 2, and no previous locoregional procedures. Conclusion Lenvatinib achieves higher ORR in all patient subgroups. Patients who achieve CR with atezolizumab plus bevacizumab can achieve OS so far never recorded in HCC patients. This study did not highlight any factors that could identify patient subgroups capable of obtaining CR.

引用

页码：5591 / 5602

页数：12

共 50 条

[1] Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study
Mara Persano
Margherita Rimini
Toshifumi Tada
Goki Suda
Shigeo Shimose
Masatoshi Kudo
Jaekyung Cheon
Fabian Finkelmeier
Ho Yeong Lim
Lorenza Rimassa
José Presa
Gianluca Masi
Changhoon Yoo
Sara Lonardi
Francesco Tovoli
Takashi Kumada
Naoya Sakamoto
Hideki Iwamoto
Tomoko Aoki
Hong Jae Chon
Vera Himmelsbach
Tiziana Pressiani
Takumi Kawaguchi
Margarida Montes
Caterina Vivaldi
Caterina Soldà
Fabio Piscaglia
Atsushi Hiraoka
Takuya Sho
Takashi Niizeki
Naoshi Nishida
Christoph Steup
Massimo Iavarone
Giovanni Di Costanzo
Fabio Marra
Mario Scartozzi
Emiliano Tamburini
Giuseppe Cabibbo
Francesco Giuseppe Foschi
Marianna Silletta
Masashi Hirooka
Kazuya Kariyama
Joji Tani
Masanori Atsukawa
Koichi Takaguchi
Ei Itobayashi
Shinya Fukunishi
Kunihiko Tsuji
Toru Ishikawa
Kazuto Tajiri
[J]. Journal of Cancer Research and Clinical Oncology, 2023, 149 : 5591 - 5602
[2] Disease etiology impact on outcomes of hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: A real-world, multicenter study
Rossari, F.
Tada, T.
Shimose, S.
Kudo, M.
Yoo, C.
Cheon, J.
Finkelmeier, F.
Lim, H. Y.
Presa, J.
Masi, G.
Bergamo, F.
Amadeo, E.
Vitiello, F.
Foti, S.
Persano, M.
Piscaglia, F.
Scartozzi, M.
Cascinu, S.
Rimini, M.
Gardini, A. Casadei
[J]. ANNALS OF ONCOLOGY, 2023, 34 : S1547 - S1547
[3] Disease etiology impact on outcomes of hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a real-world, multicenter study
Rossari, Federico
Tada, Toshifumi
Suda, Goki
Shimose, Shigeo
Kudo, Masatoshi
Yoo, Changhoon
Cheon, Jaekyung
Finkelmeier, Fabian
Lim, Ho Yeong
Presa, Jose
Masi, Gianluca
Bergamo, Francesca
Amadeo, Elisabeth
Vitiello, Francesco
Kumada, Takashi
Sakamoto, Naoya
Iwamoto, Hideki
Aoki, Tomoko
Chon, Hong Jae
Himmelsbach, Vera
Iavarone, Massimo
Cabibbo, Giuseppe
Montes, Margarida
Foschi, Francesco Giuseppe
Vivaldi, Caterina
Solda, Caterina
Sho, Takuya
Niizeki, Takashi
Nishida, Naoshi
Steup, Christoph
Hirooka, Masashi
Kariyama, Kazuya
Tani, Joji
Atsukawa, Masanori
Takaguchi, Koichi
Itobayashi, Ei
Fukunishi, Shinya
Tsuji, Kunihiko
Ishikawa, Toru
Tajiri, Kazuto
Ochi, Hironori
Yasuda, Satoshi
Toyoda, Hidenori
Ogawa, Chikara
Nishimura, Takashi
Hatanaka, Takeshi
Kakizaki, Satoru
Shimada, Noritomo
Kawata, Kazuhito
Hiraoka, Atsushi
[J]. LIVER CANCER, 2024,
[4] Atezolizumab/bevacizumab or lenvatinib in hepatocellular carcinoma: Multicenter real-world study with focus on bleeding and thromboembolic events
Ben Khaled, Najib
Moeller, Marie
Jochheim, Leonie S.
Leyh, Catherine
Ehmer, Ursula
Boettcher, Katrin
Pinter, Matthias
Balcar, Lorenz
Scheiner, Bernhard
Weich, Alexander
Leicht, Hans Benno
Zarka, Valentina
Ye, Liangtao
Schneider, Julia
Piseddu, Ignazio
Oecal, Osman
Rau, Monika
Sinner, Friedrich
Venerito, Marino
Gairing, Simon Johannes
Foerster, Friedrich
Mayerle, Julia
Toni, Enrico N. De
Geier, Andreas
Reiter, Florian P.
[J]. JHEP REPORTS, 2024, 6 (06)
[5] Effectiveness and safety of atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: A multicenter, retrospective real-world study in China
Zhang, Hui
Shao, Minghua
Tan, Binbin
Fu, Yin
Yuan
Chen, Hailei
[J]. CANCER RESEARCH, 2024, 84 (06)
[6] Comparison between Atezolizumab Plus Bevacizumab and Lenvatinib for Hepatocellular Carcinoma in Patients with Child-Pugh Class B in Real-World Clinical Settings
Ohama, Hideko
Hiraoka, Atsushi
Tada, Toshifumi
Hirooka, Masashi
Kariyama, Kazuya
Tani, Joji
Atsukawa, Masanori
Takaguchi, Koichi
Itobayashi, Ei
Fukunishi, Shinya
Tsuji, Kunihiko
Ishikawa, Toru
Tajiri, Kazuto
Ochi, Hironori
Yasuda, Satoshi
Toyoda, Hidenori
Ogawa, Chikara
Nishimura, Takashi
Hatanaka, Takeshi
Kakizaki, Satoru
Shimada, Noritomo
Kawata, Kazuhito
Naganuma, Atsushi
Kosaka, Hisashi
Matono, Tomomitsu
Shibata, Hiroshi
Aoki, Tomoko
Tada, Fujimasa
Nouso, Kazuhiro
Morishita, Asahiro
Tsutsui, Akemi
Nagano, Takuya
Itokawa, Norio
Okubo, Tomomi
Arai, Taeang
Imai, Michitaka
Koizumi, Yohei
Nakamura, Shinichiro
Iijima, Hiroko
Kaibori, Masaki
Hiasa, Yoichi
Kudo, Masatoshi
Kumada, Takashi
[J]. ONCOLOGY, 2023, 101 (09) : 542 - 552
[7] Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice
Iwamoto, Hideki
Shimose, Shigeo
Noda, Yu
Shirono, Tomotake
Niizeki, Takashi
Nakano, Masahito
Okamura, Shusuke
Kamachi, Naoki
Suzuki, Hiroyuki
Sakai, Miwa
Kajiwara, Akira
Itano, Satoshi
Tanaka, Masatoshi
Yamaguchi, Taizo
Kuromatsu, Ryoko
Koga, Hironori
Torimura, Takuji
[J]. CANCERS, 2021, 13 (11)
[8] INITIAL EXPERIENCE OF ATEZOLIZUMAB PLUS BEVACIZUMAB FOR UNRESECTABLE HEPATOCELLULAR CARCINOMA IN REAL-WORLD CLINICAL PRACTICE
Iwamoto, Hideki
Shimose, Shigeo
Takashi, Niizeki
Noda, Yu
Shirono, Tomotake
Nakano, Masahito
Okamura, Shusuke
Kamachi, Naoki
Suzuki, Hiroyuki
Kuromatsu, Ryoko
Koga, Hironori
Torimura, Takuji
[J]. HEPATOLOGY, 2021, 74 : 652A - 652A
[9] Real-world experience of atezolizumab/bevacizumab in hepatocellular carcinoma
Ha, Yeonjung
Cheon, Jaekyung
Hwang, Seong Gyu
Chon, Hong Jae
[J]. JOURNAL OF HEPATOLOGY, 2021, 75 : S526 - S527
[10] Real-world systemic treatment patterns of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma (HCC)
Singal, A. G.
Ozgurdal, K.
Fan, X.
Vassilev, Z.
Chen, C-C.
Multani, J. K.
Zhou, Z.
He, J.
Pisa, F.
[J]. ANNALS OF ONCOLOGY, 2022, 33 (07) : S867 - S867

← 1 2 3 4 5 →